Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Papers: 13 Apr 2016 - 20 Apr 2016
Psychometric Analyses to Inform Item Reduction and Evaluate Sensitivity of the Early Mobility Impairment Questionnaire for Multiple Sclerosis.
Papers: 6 Nov 2015 - 13 Nov 2015
Magnetic resonance active lesions as individual-level surrogate for relapses in multiple sclerosis.
Papers: 5 Dec 2015 - 12 Dec 2015
Cross-disease transcriptomics: Unique IL-17A signaling in psoriasis lesions and an autoimmune PBMC signature.
Papers: 14 Feb 2016 - 21 Feb 2016
Astrocyte tissue factor controls CNS hemostasis and autoimmune inflammation.
Modelling the Impact of Persistence Improvements with an Electronic Injection Device on Escalation to 2nd Line Treatment in Patients with Relapsing Remitting Multiple Sclerosis (RRMS).
Do evoked potentials contribute to the functional follow-up and clinical prognosis of multiple sclerosis?
Papers: 26 Jun 2015 - 3 Jul 2015
25 Hydroxyvitamin D and Cytokines in Multiple Sclerosis.
Evaluation of Disability Progression as an Endpoint in Clinical Trials for Relapsing-Remitting Multiple Sclerosis (RRMS): Comparison of the Define and Confirm Studies.
Papers: 23 Oct 2015 - 30 Oct 2015
A comparison of multiple sclerosis clinical disease activity between patients treated with natalizumab and fingolimod.
Olfactory dysfunction in patients with multiple sclerosis.
Histamine and Immune Biomarkers in CNS Disorders.
Elevated CSF neurofilament proteins predict brain atrophy: A 15-year follow-up study.
Pediatric Optic Neuritis Prospective Outcomes Study.
NEDA status in highly active MS can be more easily obtained with autologous hematopoietic stem cell transplantation than other drugs.
Newly Identified Gait Patterns in Patient With Multiple Sclerosis May Be Related to Push-Off Quality.
Cortical functional modifications following optic neuritis.
Susac's syndrome: Leptomeningeal enhancement on 3D FLAIR MRI.
Papers: 31 Jul 2015 - 7 Aug 2015
All relapsing multiple sclerosis patients should be managed at a specialist clinic - YES.
Pages
« first
‹ previous
…
28
29
30
31
32
33
34
35
36
…
next ›
last »
